In this video, Shahzad Raza, MD, discusses teclistamab as a potential treatment for patients with relapsed or refractory systemic light chain amyloidosis.“Teclistamab has already been approved in ...

In this video, Shahzad Raza, MD, discusses safety and efficacy data from Nexicart-2, which studied the use of chimeric antigen receptor T-cell therapy in relapsed or refractory light chain amyloidosis ...

"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

Among 83 patients receiving biologic agents for their underlying conditions and who had serum amyloid-α (AA) amyloidosis affecting the kidneys, from 60% to 88% did not develop end-stage renal disease ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

Amyloidosis is a group of conditions that cause an abnormal protein called amyloid to build up in the body. Treatment depends on the type of amyloidosis but may include medications and organ ...

AL amyloidosis can be found in newly diagnosed 2 patients with MM or can develop later in their disease course, 16 which bodes poorly for these patients. 17 Historically, the converse—that is, ...

Amyloidosis is a rare and possibly life-threatening disease affecting an estimated 4,000 people per year in the US. If left untreated, the disease can cause severe organ damage, so early detection is ...

Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, ...

Amyloidosis is a rare category of disorders in which various cells in your body function abnormally, leading to the buildup of amyloid protein. Symptoms, prognosis, diagnosis, and treatment depend ...

So, amyloidosis, there are several types, several causes, and several symptoms, so you need a comprehensive team to get together and put this puzzle together. Interviewer: Yeah, and we have a clinic ...